Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1278Carcinoma, Non-Small-Cell Lung 927Prostatic Neoplasms 729Neoplasms 633Multiple Myeloma 554Lymphoma 540Colorectal Neoplasms 530Lung Neoplasms 515Leukemia 498Leukemia, Myeloid, Acute 474Neoplasm Metastasis 471Melanoma 426Lymphoma, Non-Hodgkin 420Ovarian Neoplasms 417Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 329Head and Neck Neoplasms 307Lymphoma, Large B-Cell, Diffuse 295Glioblastoma 294Myelodysplastic Syndromes 288Lymphoma, Follicular 287Brain Neoplasms 287Stomach Neoplasms 282Carcinoma, Renal Cell 268Carcinoma, Hepatocellular 262Hodgkin Disease 261Rectal Neoplasms 256Sarcoma 250

Interventions

palbociclib 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Estrogen Receptor-positive Breast Cancer × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡